{"generic":"Ibuprofen\/Famotidine","drugs":["Duexis","Ibuprofen\/Famotidine"],"mono":[{"id":"929886-s-0","title":"Generic Names","mono":"Ibuprofen\/Famotidine"},{"id":"929886-s-1","title":"Dosing and Indications","sub":[{"id":"929886-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Gastrointestinal ulcer, Upper; Prophylaxis - Osteoarthritis:<\/b> ibuprofen 800 mg\/famotidine 26.6 mg ORALLY 3 times a day<\/li><li><b>Gastrointestinal ulcer, upper; Prophylaxis - Rheumatoid arthritis:<\/b> ibuprofen 800 mg\/famotidine 26.6 mg ORALLY 3 times a day<\/li><\/ul>"},{"id":"929886-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},{"id":"929886-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment (CrCl less than 50 mL\/min):<\/b> use not recommended "},{"id":"929886-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Gastrointestinal ulcer, Upper; Prophylaxis - Osteoarthritis<\/li><li>Gastrointestinal ulcer, upper; Prophylaxis - Rheumatoid arthritis<\/li><\/ul>"}]},{"id":"929886-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular disease or risk factors for cardiovascular disease. Famotidine\/ibuprofen is contraindicated in the perioperative setting of CABG surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal and may occur at any time and without warning. Elderly patients are at greater risk of serious gastrointestinal events.<br\/>"},{"id":"929886-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929886-s-3-9","title":"Contraindications","mono":"<ul><li>asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, history; severe and rarely fatal anaphylaxis has been reported<\/li><li>CABG surgery, treatment of perioperative pain; increased risk of myocardial infarction and stroke<\/li><li>hypersensitivity to other H2-receptor antagonists, history<\/li><li>pregnancy, late-stage (30 weeks gestation or later); may cause premature closure of the ductus arteriosus<\/li><\/ul>"},{"id":"929886-s-3-10","title":"Precautions","mono":"<ul><li>cardiovascular thrombotic events; myocardial infarction, stroke, and fatalities have been reported; risk may increase with duration of use<\/li><li>cardiovascular disease, known or risk factors; increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke<\/li><li>elderly; increased risk of serious gastrointestinal adverse events (bleeding, ulceration, perforation of stomach or intestines) that can occur at any time and without warning<\/li><li>gastrointestinal adverse events (ulceration, bleeding, or perforation of stomach or intestines), potentially fatal, may occur without warning; increased risk with concurrent use of antiplatelets (including low-dose aspirin), corticosteroids, and anticoagulants, longer duration of use, smoking, alcohol use, older age, and debilitated health status; monitoring recommended<\/li><li>active bleeding may occur; discontinue treatment if active, clinically significant bleeding from any source occurs<\/li><li>anaphylaxis may occur<\/li><li>anemia has been reported; monitoring recommended if signs and symptoms develop while on long-term therapy<\/li><li>aseptic meningitis with fever and coma has been reported, particularly in patients with systemic lupus erythematosus (SLE) and related connective tissue diseases; if signs and symptoms occur, consider a causal association to ibuprofen<\/li><li>asthma, preexisting; severe bronchospasm and fatalities have been reported<\/li><li>aspirin-sensitive asthma; risk of severe, potentially fatal bronchospasm; do not use<\/li><li>bleeding time may be prolonged in some patients, especially in comorbid coagulation disorders and concomitant anticoagulants; monitoring recommended<\/li><li>concomitant use of other ibuprofen-containing products; do not use<\/li><li>corticosteroid treatment; do not use famotidine\/ibuprofen as corticosteroid substitute or for corticosteroid insufficiency; taper corticosteroids after long-term use to avoid disease exacerbation<\/li><li>fever and inflammation may be masked<\/li><li>fluid retention or edema, new onset or exacerbation may occur<\/li><li>gastrointestinal bleeding or history of ulcer disease, especially peptic ulcers; increased risk of gastrointestinal bleed<\/li><li>heart failure; may exacerbate fluid retention and edema<\/li><li>hepatic dysfunction and abnormal liver enzymes may occur; some cases of severe injury (eg, jaundice, fulminant hepatitis, liver necrosis, and hepatic failure) including fatalities have been reported; discontinue immediately with signs or symptoms of liver disease or persistently abnormal liver tests<\/li><li>hypertension; risk of new or worsening condition; monitoring recommended<\/li><li>inflammatory bowel disease (ulcerative colitis, Crohn disease), history, may exacerbate condition<\/li><li>long-term therapy; increased risk of gastrointestinal tract ulcers and bleeding, anemia, and renal injury; monitoring recommended<\/li><li>renal insufficiency, moderate or severe (CrCl less than 50 mL\/min); potential for seizures, delirium, and coma; use of fixed-dose combination is not recommended<\/li><li>renal injury has been reported with long-term ibuprofen administration; increased risk with impaired renal function, heart failure, hepatic dysfunction, older age, and concomitant use of diuretics and ACE inhibitors; if clinical signs occur, discontinue use<\/li><li>skin reactions, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, may occur; discontinue if signs or symptoms occur<\/li><li>visual disturbances (eg, blurred\/diminished vision, scotomata, and or color vision changes); if vision disturbances occur, discontinue use<\/li><li>to report suspected adverse reactions, contact Horizon Pharma USA, Inc. at 1-866-479-6742 or the US Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929886-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"929886-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"929886-s-4","title":"Drug Interactions","sub":[{"id":"929886-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Ketorolac (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"929886-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Aspirin (probable)<\/li><li>Atazanavir (established)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clopidogrel (probable)<\/li><li>Clovoxamine (probable)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Dasatinib (established)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (established)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Femoxetine (probable)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Fluoxetine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Ginkgo (probable)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Gossypol (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Ledipasvir (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Meadowsweet (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Metronidazole (theoretical)<\/li><li>Milnacipran (probable)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nadroparin (probable)<\/li><li>Nafarelin (theoretical)<\/li><li>Nefazodone (probable)<\/li><li>Nitisinone (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rilpivirine (established)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sibutramine (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolazoline (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vismodegib (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Zimeldine (probable)<\/li><\/ul>"},{"id":"929886-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Alacepril (established)<\/li><li>Alprenolol (probable)<\/li><li>Amikacin (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Arotinolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Benazepril (established)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Cefditoren Pivoxil (probable)<\/li><li>Cefpodoxime Proxetil (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cilazapril (established)<\/li><li>Clopamide (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Delapril (established)<\/li><li>Desipramine (probable)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dilevalol (probable)<\/li><li>Diltiazem (probable)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Fluconazole (probable)<\/li><li>Flunarizine (probable)<\/li><li>Fosinopril (established)<\/li><li>Fosphenytoin (probable)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (established)<\/li><li>Lithium (probable)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moexipril (established)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pentopril (established)<\/li><li>Perindopril (established)<\/li><li>Phenytoin (probable)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Repaglinide (probable)<\/li><li>Sotalol (probable)<\/li><li>Spirapril (established)<\/li><li>Spironolactone (probable)<\/li><li>Tacrine (probable)<\/li><li>Talinolol (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Trandolapril (established)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valsartan (probable)<\/li><li>Verapamil (probable)<\/li><li>Voriconazole (established)<\/li><li>Xipamide (probable)<\/li><li>Zofenopril (established)<\/li><\/ul>"}]},{"id":"929886-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Constipation (4%), Diarrhea (5%), Indigestion (5%), Nausea (6%)<\/li><li><b>Neurologic:<\/b>Headache (3%)<\/li><li><b>Renal:<\/b>Serum creatinine raised (2% to 4%)<\/li><li><b>Respiratory:<\/b>Upper respiratory infection (4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (3%), Myocardial infarction, Thrombocytopenia<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Hepatic:<\/b>Hepatotoxicity<\/li><li><b>Neurologic:<\/b>Aseptic meningitis, Cerebrovascular accident<\/li><li><b>Renal:<\/b>Acute renal failure, Papillary necrosis<\/li><li><b>Respiratory:<\/b>Asthma<\/li><\/ul>"},{"id":"929886-s-6","title":"Drug Name Info","sub":{"0":{"id":"929886-s-6-17","title":"US Trade Names","mono":"Duexis<br\/>"},"2":{"id":"929886-s-6-19","title":"Class","mono":"<ul><li>Histamine H2 Antagonist<\/li><li>NSAID<\/li><li>Propionic Acid (class)<\/li><\/ul>"},"3":{"id":"929886-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929886-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"929886-s-7","title":"Mechanism Of Action","mono":"Famotidine is a competitive inhibitor of histamine H2-receptors that primarily inhibits both the acid concentration and volume of gastric secretion, while maintaining the changes in pepsin secretion proportional to volume output. Ibuprofen is an NSAID with analgesic and antipyretic properties that may be related to prostaglandin synthetase inhibition.<br\/>"},{"id":"929886-s-8","title":"Pharmacokinetics","sub":[{"id":"929886-s-8-23","title":"Absorption","mono":"<ul><li>Famotidine, Tmax, Oral: 2 hours<\/li><li>Famotidine, Effects of food: Tmax delayed by 1 hour; Cmax and AUC reduced by 15% and 11%, respectively<\/li><li>Ibuprofen, Tmax, Oral: 1.9 hours<\/li><li>Ibuprofen, Effects of food: Tmax delayed by 0.2 hour; AUC reduced by 14%; Cmax, no change<\/li><\/ul>"},{"id":"929886-s-8-24","title":"Distribution","mono":"<ul><li>Famotidine, Protein binding: 15% to 20%<\/li><li>Ibuprofen, Protein binding: extensive<\/li><\/ul>"},{"id":"929886-s-8-25","title":"Metabolism","mono":"<ul><li>Famotidine, Liver: 30% to 35%<\/li><li>Famotidine, Metabolite: s-oxide: activity unknown<\/li><li>Ibuprofen, Liver: extensive<\/li><li>Ibuprofen, Metabolite: 2-(p-(2carboxy-propyl) phenyl) propionic acid: activity unknown<\/li><li>Ibuprofen, Metabolite: 2-(p-(2hydroxymethyl-propyl) phenyl) propionic acid: activity unknown<\/li><li>Ibuprofen, Metabolite: conjugated ibuprofen: activity unknown<\/li><\/ul>"},{"id":"929886-s-8-26","title":"Excretion","mono":"<ul><li>Famotidine, Renal: 25% to 30% unchanged<\/li><li>Famotidine, Renal clearance: 250 to 450 mL\/min<\/li><li>Ibuprofen, Renal: Major route<\/li><\/ul>"},{"id":"929886-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Famotidine, 4 hours (healthy subjects); exceeding 20 hours (renal impairment)<\/li><li>Ibuprofen, 2 hours<\/li><\/ul>"}]},{"id":"929886-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>do not cut tablet to divide dose<\/li><li>swallow whole, do not chew or crush tablets<\/li><\/ul>"},{"id":"929886-s-10","title":"Monitoring","mono":"<ul><li>relief of signs and symptoms of rheumatoid arthritis and osteoarthritis is indicative of efficacy<\/li><li>CBC and chemistry profiles; periodically in patients on long-term therapy<\/li><li>coagulation; in patients with conditions that may be adversely affected by alterations in platelet aggregation (eg, coagulation disorders or those receiving concomitant anticoagulants)<\/li><li>hemoglobin values; periodically in patients with initial hemoglobin values of 10 g or less who require long-term therapy<\/li><li>signs and symptoms of gastrointestinal ulcers and bleeding during therapy<\/li><\/ul>"},{"id":"929886-s-11","title":"How Supplied","mono":"<b>Duexis<\/b><br\/>Oral Tablet: (Famotidine - Ibuprofen) 26.6 MG-800 MG<br\/>"},{"id":"929886-s-12","title":"Toxicology","sub":[{"id":"929886-s-12-31","title":"Clinical Effects","mono":"<ul><li><b>CIMETIDINE AND RELATED DRUGS <\/b><br\/>USES: H2 histamine blockers (or H2 blockers) are available as prescription and non-prescription medications and are used to treat reflux esophagitis, heartburn, and peptic ulcers. PHARMACOLOGY: Antagonist of H2 histamine receptors. This effect decreases gastric acid secretion. TOXICOLOGY: Cimetidine inhibits the cytochrome P450 oxidase enzymes, 1A2, C219, and 2D6, and decreases the metabolism of many other medications. EPIDEMIOLOGY: Exposures to H2 blockers are common, but significant toxicity has not been described. Adverse effects during therapeutic use are rare. MILD TO MODERATE TOXICITY: Mild drowsiness, dizziness or confusion. SEVERE TOXICITY: Severe toxicity is exceedingly rare. CNS depression and hypotension have been reported. ADVERSE EFFECTS: Dry mouth, delirium, and bone marrow suppression have been reported. Bradycardia and conduction effects are rare effects occurring mostly after rapid IV administration.<br\/><\/li><li><b>IBUPROFEN <\/b><br\/>USES: Ibuprofen is used for fever and pain control and for the treatment of several rheumatologic conditions. PHARMACOLOGY: Ibuprofen inhibits the cyclooxygenase enzyme, leading to decreased prostaglandin production and decreased pain and inflammation. TOXICOLOGY: Gastrointestinal (GI) symptoms are due to both local irritant effects and the inhibition of prostaglandins (PG), which are responsible in part for maintaining the GI mucosal barrier. Inhibition of thromboxane A2 production in platelets prolongs bleeding time and contributes to gastrointestinal bleeding. Inhibition of PGI2 and PGE2, which have vasodilatory and natriuretic activity in the kidney, can be linked to sodium and water retention and occasional acute renal failure. EPIDEMIOLOGY: Overdose is common; however, severe toxicity is very rare. MILD TO MODERATE TOXICITY: In general, patients are asymptomatic or have mild GI upset (ie, nausea, vomiting, abdominal pain). Mild CNS depression (drowsiness, lethargy) and headache are common (incidence up to 30%). Nystagmus, diplopia, headache, tinnitus, and transient deafness may also occur following overdose. SEVERE TOXICITY: With massive overdose, seizure, coma, acute renal failure, and, very rarely, cardiopulmonary arrest may occur. Upper GI bleeding may occur after acute or chronic ingestion. Elevated liver enzymes, hypoprothrombinemia, metabolic acidosis, hypokalemia, hypophosphatemia, hyponatremia, and hyperkalemia (associated with renal failure), hypotension, bradycardia, tachycardia, atrial fibrillation, dyspnea, aspiration pneumonia, rhabdomyolysis, and disseminated intravascular coagulation have also been observed in overdose. Transient episodes of apnea have been reported in young children following large ingestions. Acute pancreatitis has been reported. ONSET: Symptoms typically occur within 4 to 6 hours of ingestion. ADVERSE EFFECTS: Gastrointestinal distress, nausea, and epigastric pain are the most common findings; upper GI bleeding may occur after acute or chronic ingestion. Angioedema, hives, itching, rash, and swelling have also been reported with therapeutic use. Fluid retention, interstitial nephritis, nephritic syndrome, and acute renal failure can develop. Hematologic effects include agranulocytosis, aplastic anemia, and thrombocytopenia. Headache, asthma exacerbation, aseptic meningitis, delirium, and anaphylactoid reactions have also been reported.<br\/><\/li><\/ul>"},{"id":"929886-s-12-32","title":"Treatment","mono":"<ul><li><b>CIMETIDINE AND RELATED DRUGS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Treatment is symptomatic and supportive. MANAGEMENT OF SEVERE TOXICITY: Intravenous fluids for hypotension, supportive care for CNS depression.<\/li><li>Decontamination: PREHOSPITAL: No prehospital decontamination is recommended. HOSPITAL: No decontamination is warranted in most cases.<\/li><li>Airway management: Rare cases with significant CNS depression may require intubation for airway protection.<\/li><li>Antidote: None<\/li><li>Monitoring of patient: No specific laboratory testing is indicated in most patients. Obtain a basic metabolic screen and serum acetaminophen and salicylate concentrations after deliberate overdose.<\/li><li>Enhanced elimination procedure: Enhanced elimination is not indicated.<\/li><li>Patient disposition: HOME CRITERIA: Patients inadvertent ingestions can be managed at home. All patients with self-harm ingestions should be sent to a healthcare facility for mental health evaluation. OBSERVATION CRITERIA: Patients with deliberate overdose or more than mild symptoms should be referred to a healthcare facility and observed until symptoms resolve. ADMISSION CRITERIA: Patients with significant CNS depression or other symptoms that persist after 6 to 8 hours of observation should be admitted, but this is exceedingly rare. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance if symptoms are more than mild or if the diagnosis is unclear.<\/li><\/ul><\/li><li><b>IBUPROFEN <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Most ibuprofen toxicity resolves with supportive care. Otherwise healthy patients with a history of ibuprofen poisoning generally require only supportive care and fluid and electrolyte replacement. MANAGEMENT OF SEVERE TOXICITY: Maintain an open airway and support ventilation. Treat seizures with benzodiazepines, hypotension with fluids and adrenergic vasopressors, and coma with intubation. Monitor ECG and arterial blood gases in patients with severe toxicity.<\/li><li>Decontamination: PREHOSPITAL: Activated charcoal can be given to patients with significant overdose (more than 200 mg\/kg) who are alert and can protect their airway. HOSPITAL: Activated charcoal binds ibuprofen and should be administered after significant overdose (more than 200 mg\/kg). Gastric lavage is rarely, if ever, indicated, as this drug is absorbed rapidly and severe toxicity is exceedingly rare.<\/li><li>Airway management: Endotracheal intubation should be considered for patients who present with CNS depression (rare).<\/li><li>Antidote: None<\/li><li>Hypotensive episode: IV 0.9% NaCl 10 to 20 ml\/kg, dopamine, norepinephrine.<\/li><li>Anaphylaxis: Mild: antihistamines; Severe: airway management, epinephrine, ECG monitoring, fluids.<\/li><li>Acidosis: Administer sodium bicarbonate 1 to 2 mEq\/kg intravenously for severe acidosis (pH less than 7.1). Monitor arterial pH and blood gases to guide bicarbonate therapy.<\/li><li>Monitoring of patient: Serum ibuprofen levels are not available in most hospital laboratories and are not necessary for clinical management. Measure serum electrolytes, creatinine and BUN. If significant CNS or respiratory toxicity is present, assess acid-base status. Obtain serum acetaminophen level. Monitor for gastrointestinal bleeding.<\/li><li>Enhanced elimination procedure: Ibuprofen is highly protein-bound; hemodialysis is unlikely to be effective.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic children with inadvertent ingestions of less than 200 mg\/kg can be managed at home with milk or water dilution and observation. OBSERVATION CRITERIA: Symptomatic children, adults with deliberate ingestion, and children ingesting more than 200 mg\/kg should be referred to a health care facility for observation and treatment. Most patients who have ingested significant amounts of ibuprofen will manifest symptoms within 4 to 6 hours. ADMISSION CRITERIA: Patients who develop CNS depression, hypotension, acidosis, or gastrointestinal bleeding should be admitted.<\/li><\/ul><\/li><\/ul>"},{"id":"929886-s-12-33","title":"Range of Toxicity","mono":"<ul><li><b>CIMETIDINE AND RELATED DRUGS<\/b><br\/>TOXICITY: These medications have a large therapeutic window and no more than minimal toxicity is expected even with very large overdoses. THERAPEUTIC DOSE: CIMETIDINE: ADULT: 400 to 1600 mg\/day orally; PEDIATRIC: 20 to 40 mg\/kg\/day orally. FAMOTIDINE: ADULT: 20 to 80 mg\/day orally; PEDIATRIC: 0.5 to 2 mg\/kg\/day orally. RANITIDINE: ADULT: 150 to 300 mg\/day orally; PEDIATRIC: 2 to 10 mg\/kg\/day orally, divided in 2 to 4 doses.<br\/><\/li><li><b>IBUPROFEN<\/b><br\/>TOXICITY: Ingestions of less than 200 mg\/kg rarely cause significant toxicity; ingestions of greater than 400 mg\/kg may result in serious effects. ADULTS: Overdoses of up to 48 g have been well tolerated by healthy adults. An adult died following an overdose of 105 g of sustained-release ibuprofen. THERAPEUTIC DOSE: ADULT: OTC: 200 mg orally every 4 to 6 hours as needed; PRESCRIPTION: 400 to 800 mg orally every 6 to 8 hours as needed. PEDIATRIC: OTC: 5 to 10 mg\/kg.<br\/><\/li><\/ul>"}]},{"id":"929886-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise female patients to avoid taking late in pregnancy, as drug may cause premature closure of the ductus arteriosus.<\/li><li>Drug may cause nausea, diarrhea, constipation, upper abdominal pain, and headaches.<\/li><li>Instruct patient to report signs\/symptoms of serious gastrointestinal events such as bleeding, ulceration, or perforation of stomach or intestines.<\/li><li>Advise patient to report signs\/symptoms of myocardial infarction, thrombotic events, or stroke.<\/li><li>Tell patient to report signs\/symptoms of skin rash, Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, or skin\/mucous membrane blistering), or toxic epidermal necrolysis (widespread peeling\/blistering of skin).<\/li><li>Instruct patient to swallow tablet whole and not to cut, divide, chew, or crush tablet.<\/li><li>Advise patient not to take additional ibuprofen-containing products or NSAIDs, including over-the-counter (OTC) medications, unless approved by physician.<\/li><\/ul>"}]}